Eighty-five people with long COVID. Eighty-five people who caught the same virus in 2020 and got better within three months. Matched for age, matched for sex, and all of them giving blood somewhere between one and two years after their infection. That symmetry is the backbone of a new preprint from researchers in Zaragoza and Toulouse, and it is what makes their central result worth sitting with: when the team looked hard for the inflammation that many people expect to find in long COVID, it was not there.
The study builds on work the same group published earlier. In that first round, they compared the two groups across a wide spread of routine measures: blood cell counts, coagulation status, standard SARS-CoV-2 antibody tests, immune cell populations, and cytokine levels read out on a Luminex platform. Cytokines are the small signalling proteins immune cells use to talk to each other, and they are the usual suspects when researchers go looking for a body stuck in a low-grade alarm state.
The problem with cytokines is that they are hard to measure well. They circulate at vanishingly low concentrations, and multiplex assays that read many of them at once can be noisy at the bottom of their range. So the team went back and did it again with better instruments. They rebuilt the panel around ELLA, an automated immunoassay system designed for high-precision quantification, and focused on four classical markers of systemic inflammation: C-reactive protein, the general-purpose inflammation signal clinicians order every day; tumour necrosis factor alpha; interleukin-1 beta; and interleukin-6.
The title of the paper states the outcome plainly. High quality analysis of circulating biomarkers reveals no evidence of elevated inflammatory markers in this cohort. In the manuscript, the authors report data confirming that their long COVID and control groups really were matched on age and sex, and they compare the two groups on cytokine levels and on comorbidities, the other health conditions participants were carrying alongside their post-COVID symptoms.
What a negative result is and is not
It would be easy to read this as a verdict on long COVID itself. It is not, and the authors do not frame it that way. The finding is specific: in these 170 people, recruited through a primary care centre and assessed twelve to twenty-four months after infection, the blood did not show elevated levels of four widely used inflammation markers.
Who gets recruited matters enormously here. A primary care centre sees the broad middle of a population, not the sickest tail that ends up in hospital-based specialist clinics. Long COVID, as the authors describe it, is a broad label covering a heterogeneous set of long-term consequences that persist for at least three months after infection. A label that broad almost guarantees that different cohorts contain different mixtures of people, which is one reason results across long COVID biomarker studies have been so hard to reconcile.
It is also worth being precise about what the comparison group was. These were not people who had never had COVID. They were people who caught SARS-CoV-2 in 2020 and recovered within three months. That is the harder and more useful control: it isolates whatever is different about not recovering, rather than simply detecting the footprint of having been infected at all.
The study is a preprint posted to medRxiv, which means it has not yet cleared peer review. The authors declare no competing interests, list ethics approval from the Research Ethics Committee of the Community of Aragon, and say they obtained written informed consent from every participant. Their earlier data are already public on Zenodo, and they state that the new data will be posted there too.
Why it matters
The search for a long COVID blood test has been going on for years, and it has not succeeded. As the authors put it, there is still no reliable biomarker or panel that can separate people with long COVID from healthy people or from those who recovered from acute infection. That absence has real consequences for patients, who often face diagnosis by exclusion and, too often, doubt about whether anything measurable is wrong.
Careful negative results do useful work in that situation. If ongoing peripheral inflammation, the kind that shows up as raised CRP or IL-6 in a blood draw, is not a general feature of long COVID in a primary care population, then researchers hunting for mechanisms and diagnostics have reason to look elsewhere: at tissue rather than circulating blood, at other biological systems, or at subgroups within the label rather than the label as a whole. Ruling something out narrows the field.
It also matters for how clinicians interpret a normal blood panel. A patient with persistent symptoms and unremarkable inflammatory markers is not, on this evidence, an anomaly. That is quietly reassuring in one direction and frustrating in another, because it means the tests most readily available in a GP's surgery are unlikely to be the ones that eventually explain what is happening.
One cohort in one region of Spain cannot settle any of this. But it adds a well-matched, carefully measured data point to a literature that badly needs them.